[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-442954-en":59,"doc-seo-442954-105":80},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":72,"language_code":73,"site_id":74,"html_lang":73,"table_of_contents":75,"faqs":76,"seo_title":77,"seo_description":66,"update_tm":78,"read_time":79},442954,3985747870733,"acoobca","https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","A multicenter, observational study to evaluate the safety of restarting antitumor therapy recovered from COVID-19","Cancer patients face a higher risk of adverse effects from coronavirus disease 2019 (COVID-19) than the general population, yet the safety of restarting antitumor therapy after recovery remains unclear. This prospective multicenter study screened 419 recovered cancer patients across four centers and followed treatment-emergent adverse events in the first resumed cycle within 3 months. Secondary analyses evaluated changes in clinical laboratory parameters. Among 270 included participants, common grade 3+ TEAEs included fatigue, anemia, leukopenia, and alanine transaminase elevation, with no observed severe cardiac toxicity.","FUTURE ONCOLOGY  \n2026, VOL. 22, NO. 1, 83–91  \n[https://doi.org/10.1080/14796694.2025.2595908](https://doi.org/10.1080/14796694.2025.2595908)  \n| RESEARCH ARTICLE   \u003Cbr>A multicenter, observational study to evaluate the safety of restarting antitumor therapy recovered from COVID-19\u003Cbr>Liting Guo a*, Chenfei Zhoua*, Wenqi Xia*, Liu Yanga*, Qing Changb, Qing Qua, Jinling Jianga, Junwei Wua, Qu Caia, Jun Yanc, Chun Wangc, Yanzhi Bid, Xuyang Wene,f, Feng Qia and Jun Zhanga\u003Cbr>aDepartment of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; bDepartment of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; cDepartment of Oncology, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China; dDepartment of Oncology, Changzhou Tumor Hospital Affiliated to Soochow University, Changzhou, China; e Department of Oncology, Haowangjiao Hospital, Shanghai, China; fDepartment of Oncology, The 82nd Hospital of the PLA, Huaian, Jiangsu, China |  |  |\n| --- | --- | --- |\n| ABSTRACT\u003Cbr>Aims: Cancer patients face a higher risk of adverse effects from coronavirus disease 2019 (COVID-19) compared to the general population. However, the safety of restarting antitumor therapy following COVID-19 recovery remains unclear.\u003Cbr>Methods: In this prospective, multicenter study conducted between January 1 and 30 March 2023, 419 eligible cancer patients who had recovered from COVID-19 were screened across four medical centers. The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs) during the first cycle of antitumor therapy resumed within 3 months after COVID-19 recovery. Changes in clinical laboratory parameters were assessed as secondary endpoints.\u003Cbr>Results: A total of 270 eligible participants were included in this study. The common grade 3 or worse TEAEs were fatigue (3.3%), anemia (1.1%), leukopenia (0.7%), and elevated alanine transaminase (0.3%) . No severe cardiac toxicity and significant abnormalities on the chest computed tomography (CT) were observed. D-dimer and cardiac troponin I (cTNI) were significantly increased after treatment (p \u003C 0.05) . Increased inflammatory cytokines of peripheral blood could be observed after administration ofoxaliplatin and trastuzumab.\u003Cbr>Conclusions: Restarting systemic antitumor therapy in solid tumor patients after COVID-19 recovery is generally safe. Systemic inflammatory and coagulation function of patients should be monitored during treatment.\u003Cbr>PLAIN LANGUAGE SUMMARY\u003Cbr>There have been very few studies so far that closely followed Chinese cancer patients recovering from coronavirus disease 2019 (COVID-19) to see how safe for them to restart cancer treatment. Our research, the multicenter, observational study shows that restarting treatment is generally safe, even for patients with advanced cancer. We did not observe any serious heart or lung side effects. However, we did notice increases in certain blood markers related to inflammation and clotting after treatment. These changes likely reflect the body’s response to having had COVID-19 . We recommend monitoring these blood markers during treatment to keep patients safe. |  | ARTICLE HISTORY\u003Cbr>Received 14 March 2025 Accepted 24 November 2025\u003Cbr>KEYWORDS\u003Cbr>COVID-19; safety; restarting antitumor therapy; clinical trial; solid tumors |\n| 1. Introduction | substantial cancer burden, the suspension or discontinuation |  |\n| The pandemic of coronavirus disease 2019 (COVID-19), caused | of antitumor therapy due to comorbidities can seriously affect |  |\n| by severe acute respiratory syndrome coronavirus type 2 | the overall prognosis of cancer patients [4] . |  |\n| (SARS-CoV-2) infection, has significantly impacted paradigms | Current evidence provides limited guidance regarding the |  |\n| of cancer treatment. Cancer patients usually have immune | optimal timing for resuming antitumor therapy followi","cbCaisaH02B5SbaE","https://ap.wps.com/l/cbCaisaH02B5SbaE","pdf",3737335,"English","en",105,"# Abstract\n## Aims\n## Methods\n## Results\n## Conclusions\n# Plain language summary\n# Article history\n# Keywords\n# 1. Introduction","[{\"question\":\"What question does the study address about cancer treatment after COVID-19 recovery?\",\"answer\":\"It evaluates whether restarting systemic antitumor therapy is safe in solid tumor patients after recovering from COVID-19, focusing on early treatment-emergent adverse events within the first resumed cycle.\"},{\"question\":\"How was the study designed and when were patients assessed?\",\"answer\":\"The study was prospective and multicenter, screening eligible cancer patients recovered from COVID-19 across four medical centers. The primary assessment covered treatment-emergent adverse events during the first cycle of resumed antitumor therapy within 3 months after recovery.\"},{\"question\":\"What adverse event findings were reported after restarting therapy?\",\"answer\":\"Common grade 3 or worse treatment-emergent adverse events included fatigue, anemia, leukopenia, and elevated alanine transaminase. The study reported no severe cardiac toxicity and no significant abnormalities on chest CT, while specific blood markers such as D-dimer and cardiac troponin I increased after treatment.\"}]","A multicenter, observational study to evaluate the safety of restarting antitumor therapy recovered from COVID-19 | PDF",1790702296,23,{"code":4,"msg":81,"data":82},"ok",{"site_id":74,"language":73,"slug":83,"title":65,"keywords":84,"description":66,"schema_data":85,"social_meta":139,"head_meta":141,"extra_data":143,"updated_unix":144},"a-multicenter-observational-study-to-evaluate-the-safety-of-restarting-antitumor-therapy-recovered-from-covid-19","",{"@graph":86,"@context":138},[87,101,121],{"@type":88,"itemListElement":89},"BreadcrumbList",[90,94,96,99],{"item":91,"name":92,"@type":93,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":95,"name":9,"@type":93,"position":14},"https://docshare.wps.com/document/",{"item":97,"name":40,"@type":93,"position":98},"https://docshare.wps.com/document/research-report/",3,{"item":100,"name":65,"@type":93,"position":19},"https://docshare.wps.com/document/a-multicenter-observational-study-to-evaluate-the-safety-of-restarting-antitumor-therapy-recovered-from-covid-19/442954/",{"url":100,"name":65,"@type":102,"image":103,"author":108,"headline":65,"publisher":110,"fileFormat":113,"inLanguage":73,"description":66,"dateModified":114,"datePublished":115,"encodingFormat":113,"isAccessibleForFree":116,"interactionStatistic":117},"DigitalDocument",{"url":104,"@type":105,"width":106,"height":107},"https://docshare.wps.com/thumbnails/a-multicenter-observational-study-to-evaluate-the-safety-of-restarting-antitumor-therapy-recovered-from-covid-19/442954.png","ImageObject",300,407,{"name":63,"@type":109},"Person",{"url":91,"name":111,"@type":112},"DocShare","Organization","application/pdf","2026-10-01","2026-09-29",true,{"@type":118,"interactionType":119,"userInteractionCount":14},"InteractionCounter",{"@type":120},"ViewAction",{"@type":122,"mainEntity":123},"FAQPage",[124,130,134],{"name":125,"@type":126,"acceptedAnswer":127},"What question does the study address about cancer treatment after COVID-19 recovery?","Question",{"text":128,"@type":129},"It evaluates whether restarting systemic antitumor therapy is safe in solid tumor patients after recovering from COVID-19, focusing on early treatment-emergent adverse events within the first resumed cycle.","Answer",{"name":131,"@type":126,"acceptedAnswer":132},"How was the study designed and when were patients assessed?",{"text":133,"@type":129},"The study was prospective and multicenter, screening eligible cancer patients recovered from COVID-19 across four medical centers. The primary assessment covered treatment-emergent adverse events during the first cycle of resumed antitumor therapy within 3 months after recovery.",{"name":135,"@type":126,"acceptedAnswer":136},"What adverse event findings were reported after restarting therapy?",{"text":137,"@type":129},"Common grade 3 or worse treatment-emergent adverse events included fatigue, anemia, leukopenia, and elevated alanine transaminase. The study reported no severe cardiac toxicity and no significant abnormalities on chest CT, while specific blood markers such as D-dimer and cardiac troponin I increased after treatment.","https://schema.org",{"og:url":100,"og:type":140,"og:title":65,"og:site_name":111,"og:description":66},"article",{"robots":142,"canonical":100},"index,follow",{"doc_id":61,"site_id":74},1790839211]